

FY 2021 Additional Information

3Q 2020 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions

differences due to rounding

	A	B	C	A - B - C
	IFRS Q3 2020	Incyte Collaboration	Royalty Pharma	A - B - C
Revenues	22.0	2.2	-	19.8
Monjuvi US product sales	4.4	2.2 ¹⁾		2.2
Royalties	10.2		5)	10.2
Other	7.4			7.4
Cost of Sales	(3.7)	(0.2)	-	(3.5)
Cost of Sales US Monjuvi product sales	(0.4)	(0.2) ²⁾		(0.2)
Other	(3.3)			(3.3)
Gross Profit	18.3	2.0	-	16.3
<i>Gross Margin</i>	83.2%			82.2%
Total Operating Expenses:	(80.3)	(12.2)	-	(68.1)
Research and Development	(34.1)			(34.1)
Selling	(32.9)	(12.2) ³⁾		(20.7)
General and Administrative	(13.3)			(13.3)
Operating Profit/(Loss)	(62.0)	(10.2)	-	(51.8)
<i>Operating Margin</i>	-282%			-262%
Other Income	1.7			1.7
Other Expenses	(1.3)			(1.3)
Finance Income	32.4	33.0 ⁴⁾		(0.6)
Finance Expenses	(67.6)	(60.5) ⁴⁾		(7.1)
Effects from Impairment on Financial Assets	(0.4)			(0.4)
Income Tax Benefit / (Expenses)	31.8			31.8
Consolidated Net Profit/(Loss)	(65.4)	(37.7)	-	(27.7)
EPS, Basic and Diluted	(2.00)			(0.85)
EPS, Basic	-			-
EPS, Diluted	-			-
Shares Used for EPS, Basic	32.72			32.72
Shares Used for EPS, Diluted				

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.

4Q 2020 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions

differences due to rounding

	A IFRS Q4 2020	B Incyte Collaboration	C Royalty Pharma	A - B - C
Revenues	36.0	7.1	-	29.0
Monjuvi US product sales	14.1	7.1 ¹⁾		7.1
Royalties	12.1		5)	12.1
Other	9.8			9.8
Cost of Sales	(9.4)	(1.2)	-	(8.3)
Cost of Sales US Monjuvi product sales	(2.4)	(1.2) ²⁾		(1.2)
Other	(7.1)			(7.1)
Gross Profit	26.6	5.9	-	20.7
<i>Gross Margin</i>	73.8%			71.5%
Total Operating Expenses:	(101.8)	(15.9)	-	(85.9)
Research and Development	(52.8)			(52.8)
Selling	(32.8)	(15.9) ³⁾		(16.9)
General and Administrative	(14.2)			(14.2)
Impairment of Goodwill	(2.1)			(2.1)
Operating Profit/(Loss)	(75.2)	(10.0)	-	(65.2)
<i>Operating Margin</i>	-209%			-225%
Other Income	2.9			2.9
Other Expenses	(2.2)			(2.2)
Finance Income	31.6	26.7 ⁴⁾		4.9
Finance Expenses	5.7	(21.7) ⁴⁾		27.4
Effects from Impairment on Financial Assets	0.4			0.4
Income Tax Benefit / (Expenses)	20.2			20.2
Consolidated Net Profit/(Loss)	(16.6)	(5.0)	-	(11.6)
EPS, Basic and Diluted	(0.50)			(0.35)
EPS, Basic	-			-
EPS, Diluted	-			-
Shares Used for EPS, Basic	32.76			32.76
Shares Used for EPS, Diluted				

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.

1Q 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions

differences due to rounding

	A	B	C	A - B - C
	IFRS Q1 2021	Incyte Collaboration	Royalty Pharma	A - B - C
Revenues	47.2	6.5	-	40.8
Monjuvi US product sales	12.9	6.5 ¹⁾	-	6.5
Royalties	11.6	-	5)	11.6
Other	22.7	-	-	22.7
Cost of Sales	(5.0)	(1.1)	-	(3.9)
Cost of Sales US Monjuvi product sales	(2.2)	(1.1) ²⁾	-	(1.1)
Other	(2.8)	-	-	(2.8)
Gross Profit	42.2	5.4	-	36.9
<i>Gross Margin</i>	89.4%	-	-	90.4%
Total Operating Expenses:	(71.8)	(12.8)	-	(59.0)
Research and Development	(33.3)	-	-	(33.3)
Selling	(28.2)	(12.8) ³⁾	-	(15.4)
General and Administrative	(10.3)	-	-	(10.3)
Operating Profit/(Loss)	(29.6)	(7.5)	-	(22.2)
<i>Operating Margin</i>	-63%	-	-	-54%
Other Income	1.2	-	-	1.2
Other Expenses	(2.0)	-	-	(2.0)
Finance Income	13.9	2.4 ⁴⁾	-	11.5
Finance Expenses	(39.7)	(34.9) ⁴⁾	-	(4.8)
Effects from Impairment on Financial Assets	0.1	-	-	0.1
Income Tax Benefit / (Expenses)	14.5	-	-	14.5
Consolidated Net Profit/(Loss)	(41.6)	(40.0)	-	(1.7)
EPS, Basic and Diluted	(1.27)	-	-	(0.05)
EPS, Basic	-	-	-	-
EPS, Diluted	-	-	-	-
Shares Used for EPS, Basic	32.76	-	-	32.76
Shares Used for EPS, Diluted	-	-	-	-

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.

2Q 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions

differences due to rounding

	A	B	C	A - B - C
	IFRS Q2 2021	Incyte Collaboration	Royalty Pharma	A - B - C
Revenues	38.2	7.5	13.7	17.1
Monjuvi US product sales	14.9	7.5 ¹⁾		7.5
Royalties	13.7		13.7 ⁵⁾	-
Other	9.6			9.6
Cost of Sales	(10.1)	(1.4)	-	(8.7)
Cost of Sales US Monjuvi product sales	(2.8)	(1.4) ²⁾		(1.4)
Other	(7.3)			(7.3)
Gross Profit	28.1	6.1	13.7	8.4
<i>Gross Margin</i>	73.6%			49.1%
Total Operating Expenses:	(99.5)	(13.7)	-	(85.8)
Research and Development	(40.5)			(40.5)
Selling	(28.5)	(13.7) ³⁾		(14.8)
General and Administrative	(30.5)			(30.5)
Operating Profit/(Loss)	(71.4)	(7.6)	13.7	(77.4)
<i>Operating Margin</i>	-187%			-454%
Other Income	1.7			1.7
Other Expenses	(1.4)			(1.4)
Finance Income	102.4	105.8 ⁴⁾		(3.4)
Finance Expenses	2.9	7.5 ⁴⁾		(4.6)
Effects from Impairment on Financial Assets	0.2			0.2
Income Tax Benefit / (Expenses)	(13.5)			(13.5)
Consolidated Net Profit/(Loss)	20.9	105.7	13.7	(98.4)
EPS, Basic and Diluted	-			
EPS, Basic	0.64			(3.00)
EPS, Diluted	0.61			(2.78)
Shares Used for EPS, Basic	32.78			32.78
Shares Used for EPS, Diluted	35.37			35.37

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.

3Q 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions <i>differences due to rounding</i>	A	B	C	A - B - C
	IFRS Q3 2021	Incyte Collaboration	Royalty Pharma	
Revenues	41.2	9.3	16.9	15.0
Monjuvi US product sales	18.6	9.3 ¹⁾		9.3
Royalties	17.0		16.9 ⁵⁾	0.1
Other	5.6			5.6
Cost of Sales	(7.5)	(1.8)	-	(5.7)
Cost of Sales US Monjuvi product sales	(3.6)	(1.8) ²⁾		(1.8)
Other	(3.9)			(3.9)
Gross Profit	33.7	7.5	16.9	9.3
<i>Gross Margin</i>	81.8%			62.0%
Total Operating Expenses:	(116.1)	(14.5)	-	(101.7)
Research and Development	(64.4)			(64.4)
Selling	(32.4)	(14.5) ³⁾		(17.9)
General and Administrative	(19.4)			(19.4)
Operating Profit/(Loss)	(82.4)	(6.9)	16.9	(92.4)
<i>Operating Margin</i>	-200%			-616%
Other Income	2.0			2.0
Other Expenses	(1.2)			(1.2)
Finance Income	(17.0)	(24.8) ⁴⁾	- ⁶⁾	7.8
Finance Expenses	(55.7)	(16.3) ⁴⁾	(31.9) ⁶⁾	(7.5)
Effects from Impairment on Financial Assets	0.3			0.3
Income Tax Benefit / (Expenses)	41.2			41.2
Consolidated Net Profit/(Loss)	(112.8)	(48.0)	(15.0)	(49.8)
EPS, Basic and Diluted	(3.30)			(1.46)
EPS, Basic	-			-
EPS, Diluted	-			-
Shares Used for EPS, Basic	34.13			34.13
Shares Used for EPS, Diluted				

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward
- 6) Valuation effects from Royalty Pharma financial liability (actual and planning cash flow adjustments incl. fx effects, interest expense)

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.

4Q 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions

differences due to rounding

	A	B	C	A - B - C
	IFRS Q4 2021	Incyte Collaboration	Royalty Pharma	A - B - C
Revenues	52.9	10.3	22.6	20.1
Monjuvi US product sales	20.5	10.3 ¹⁾		10.3
Royalties	23.2		22.6 ⁵⁾	0.6
Other	9.3			9.3
Cost of Sales	(9.5)	(1.6)	-	(7.9)
Cost of Sales US Monjuvi product sales	(3.8)	(1.6) ²⁾		(2.2)
Other	(5.7)			(5.7)
Gross Profit	43.4	8.7	22.6	12.2
<i>Gross Margin</i>	82.0%			60.5%
Total Operating Expenses:	(368.4)	(15.2)	-	(353.2)
Research and Development	(87.0)			(87.0)
Selling	(32.5)	(15.2) ³⁾		(17.3)
General and Administrative	(18.2)			(18.2)
Impairment of Goodwill	(230.7) ⁷⁾			(230.7)
Operating Profit/(Loss)	(325.0)	(6.5)	22.6	(341.0)
<i>Operating Margin</i>	-614%			-1697%
Other Income	3.4			3.4
Other Expenses	(1.7)			(1.7)
Finance Income	(2.7)	(7.7) ⁴⁾	- ⁶⁾	5.0
Finance Expenses	(89.0)	(16.0) ⁴⁾	(62.8) ⁶⁾	(10.2)
Effects from Impairment on Financial Assets	(0.2)			(0.2)
Income Tax Benefit / (Expenses)	34.4			34.4
Consolidated Net Profit/(Loss)	(380.9)	(30.2)	(40.2)	(310.5)
EPS, Basic and Diluted	(11.16)			(9.09)
EPS, Basic	-			-
EPS, Diluted	-			-
Shares Used for EPS, Basic	34.15			34.15
Shares Used for EPS, Diluted				

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward
- 6) Valuation effects from Royalty Pharma financial liability (actual and planning cash flow adjustments incl. fx effects, interest expense)
- 7) Write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals, Inc.

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.

FY 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma

Euros in millions

differences due to rounding

	A	B	C	A - B - C
	IFRS FY 2021	Incyte Collaboration	Royalty Pharma	A - B - C
Revenues	179.6	33.5	53.2	93.0
Monjuvi US product sales	66.9	33.5 ¹⁾		33.5
Royalties	65.6		53.2 ⁵⁾	12.4
Other	47.2			47.2
Cost of Sales	(32.2)	(5.2)	-	(26.8)
Cost of Sales US Monjuvi product sales	(12.3)	(5.2) ²⁾		(7.1)
Other	(19.7)			(19.7)
Gross Profit	147.4	28.2	53.2	66.2
<i>Gross Margin</i>	82.1%			71.1%
Total Operating Expenses:	(655.8)	(56.2)	-	(369.0)
Research and Development	(225.2)			(225.2)
Selling	(121.6)	(56.2) ³⁾		(65.4)
General and Administrative	(78.4)			(78.4)
Impairment of Goodwill	(230.7) ⁷⁾			(230.7)
Operating Profit/(Loss)	(508.4)	(27.9)	53.2	(302.8)
<i>Operating Margin</i>	-283%			-326%
Other Income	8.3			8.3
Other Expenses	(6.3)			(6.3)
Finance Income	96.6	75.7 ⁴⁾	- ⁶⁾	20.9
Finance Expenses	(181.5)	(59.7) ⁴⁾	(94.7) ⁶⁾	(27.1)
Effects from Impairment on Financial Assets	0.4			0.4
Income Tax Benefit / (Expenses)	76.6			76.6
Consolidated Net Profit/(Loss)	(514.4)	(11.9)	(41.5)	(230.1)
EPS, Basic and Diluted	(15.40)			(6.89)
EPS, Basic	-			-
EPS, Diluted	-			-
Shares Used for EPS, Basic	33.40			33.40
Shares Used for EPS, Diluted				

Legend

- 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business
- 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR
- 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR
- 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense)
- 5) Tremfya royalty paid to Royalty Pharma
- 6) Valuation effects from Royalty Pharma financial liability (actual and planning cash flow adjustments incl. fx effects, interest expense)
- 7) Write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals, Inc.

We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.